港股異動 | 檸萌影視上市第3日飆漲超17%創新高 市值首超百億港元
格隆匯8月12日丨檸萌影視(9857.HK)快速拉昇飆漲超17%,最高報31.6港元創上市新高價,市值站上百億港元。招股書披露,檸萌影視成立以來共製作及發行17部劇集,其中15部為公司擔任牽頭或獨家投資者及執行製片人的版權劇。根據弗若斯特沙利文的統計數據,2019年至2021年公司已播映的八部版權劇中有六部屬於高收視率劇集,高收視率劇集率高達約75.0%,遠超同期按收入劃分的前五大競爭對手約45.9%的平均高收視率劇集率。近期影視行業積極信號頻出,國家電影局聯合多家電影票務平台發放共計1億元觀影消費券,東北證券認為,影視行業復甦在即。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.